Climb Bio, Inc.
NASDAQ:CLYMBiotechnology
+$0.02 today
- Market cap
- $546.27M
- Beta
- 0.10
- P/E (TTM)
- -14.7
- EPS (TTM)
- -$0.77
Volume 0.87M
Average 0.88M
CLYM Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Climb Bio, Inc.NASDAQ: CLYM
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables outflow grows to $0
Q1 FY2026 accounts receivables was $0, compared with $0 a year earlier. Trailing-twelve-month accounts receivables was $0.
Context
- Accounts receivables increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Accounts Receivables vs competitors
How CLYM compares with its peers on the latest reported figures
- CLYM's LTM Mar 2026 accounts receivables of $0 is the 2nd largest of the 5 companies compared; the peer median is $0.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
UPBUpstream Bio, Inc. | LTM Mar 2026 | $468K | -372.1% | -48.9% | 14.1% |
CLYMClimb Bio, Inc. | LTM Mar 2026 | $0 | — | — | — |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $0 | — | — | — |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding CLYM) | $0 | -372.1% | -48.9% | 14.1% | |
Competitors are the stored peer set for CLYM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (47.48M) | (45.24M) | (35.12M) | (73.9M) | (59.85M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 97K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.74M | 6.99M | 12.81M | 5.56M | 8.05M |
| Change in Working Capital | (4.17M) | 210K | 3.76M | 1.7M | (601K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 318K | (653K) | (686K) | (1.14M) | 1.56M |
| Other Working Capital | (4.49M) | 863K | 4.45M | 2.84M | (2.17M) |
| Other Non-Cash Items | 11.84M | 674K | (2.05M) | 51.08M | (2.06M) |
| Operating Cash Flow | (36.07M) | (37.37M) | (20.6M) | (15.56M) | (54.36M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | (186K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (114.97M) | (87.96M) | (58.45M) | (132.2M) | (108.08M) |
| Sales of Investments | 0 | 122.4M | 127.43M | 20.75M | 111.1M |
| Other Investing Activities | 0 | 0 | 0 | (9.65M) | 0 |
| Investing Cash Flow | (114.97M) | 34.44M | 68.98M | (121.09M) | 2.83M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 83.14M | 0 | 841K | 119.75M | (21K) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 149K | 0 | 0 | 10.98M | 0 |
| Financing Cash Flow | 177.23M | 0 | 841K | 130.73M | (21K) |
| Effect of Forex Changes | 245K | (408K) | 304K | 42K | 0 |
| Net Change in Cash | 26.44M | (3.34M) | 49.53M | (5.88M) | (51.54M) |
| Free Cash Flow | (36.07M) | (37.37M) | (20.6M) | (15.56M) | (54.54M) |
Climb Bio, Inc.
NASDAQ:CLYM
Intrinsic Alpha fair value
Locked
Current Price
$9.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.